Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W
Clin Cancer Res. 2014 20 (9): 2264-75

PMID: 24599935 · PMCID: PMC4008689 · DOI:10.1158/1078-0432.CCR-13-1591

Increased understanding of intertumoral heterogeneity at the genomic level has led to significant advancements in the treatment of solid tumors. Functional genomic alterations conferring sensitivity to targeted therapies can take many forms, and appropriate methods and tools are needed to detect these alterations. This review provides an update on genetic variability among solid tumors of similar histologic classification, using non-small cell lung cancer and melanoma as examples. We also discuss relevant technological platforms for discovery and diagnosis of clinically actionable variants and highlight the implications of specific genomic alterations for response to targeted therapy.

©2014 AACR.

MeSH Terms (20)

Anaplastic Lymphoma Kinase Animals Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Cell Transformation, Neoplastic Drug Resistance, Neoplasm Genetic Testing Genetic Variation Genomics Genomics Genotype Humans Lung Neoplasms Melanoma Molecular Targeted Therapy Mutation Neoplasms Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf Receptor Protein-Tyrosine Kinases

Connections (5)

This publication is referenced by other Labnodes entities: